Special Issue "Targeting β-lactamases to Fight Bacterial Resistance to β-lactam Antibiotics"
A special issue of Antibiotics (ISSN 2079-6382).
Deadline for manuscript submissions: closed (29 February 2020) | Viewed by 40490
Interests: X-ray crystallography; structural biology; β-lactamases; antibiotic resistance; bacterial thymidylate synthase; human thymidylate synthase; pteridine reductase; Heat shock protein 90 N-terminal domain; Hippo-pathway; 14-3-3; bioinorganic chemistry; ferritin; glutaminyl cyclase
Special Issues, Collections and Topics in MDPI journals
Special Issue in Antibiotics: Recent Advances in the Development of Beta-Lactamase Inhibitors
In bacteria, a major resistance mechanism to β-lactam antibiotics is represented by the production of one or more β-lactamase enzymes. β-Lactamases belong to two structurally and mechanistically unrelated families of enzymes, the serine-β-lactamases (SBLs; classes A, C, and D) and the metallo-β-lactamases (MBLs; class B). Recently, there has been renewed interest in discovering novel inhibitors to counter the threat from newer β-lactamases, such as the extended spectrum β-lactamases (ESBLs) and carbapenemases, which are not inhibited by the classical SBL inhibitors clavulanic acid and tazobactam. Two new SBL inhibitors, the diazabicyclooctane (DBO) avibactam and the boronate vaborbactam, which are used in combination with ceftazidime and meropenem, respectively, have been recently developed. However, as of yet, there are no MBL inhibitors in clinical use despite there being a clear unmet medical need.
This Special Issue features multidisciplinary research focused on β-lactamase enzymes to provide new insight into these key targets to fight bacteria resistance to β-lactam antibiotics. The main topics covered by this Special Issue are the identification and characterization of serine- and metallo-β-lactamase enzymes, mechanistic and structural studies, and the identification and development of SBL and MBL inhibitors.
Dr. Cecilia Pozzi
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- β-lactam antibiotics
- β-lactamase inhibitors
- extended spectrum β-lactamases